Enclomiphene Citrate Cost in Mississippi 2026

What Enclomiphene Citrate Is and Why It Matters for Mississippi Men

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen-receptor modulator (SERM) that blocks hypothalamic estrogen receptors and triggers a rise in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The result is endogenous testosterone production rather than the exogenous testosterone replacement that suppresses sperm production. For men in Mississippi who want to restore testosterone while preserving fertility, that pharmacological distinction is clinically meaningful.

Secondary hypogonadism affects an estimated 2.1% to 5.7% of adult men in population surveys [1]. Mississippi carries above-average rates of obesity, type 2 diabetes, and metabolic syndrome, all of which are independently associated with hypothalamic-pituitary suppression and secondary hypogonadism [2]. A 2016 study by Kim et al. published in BJU International (N=303) demonstrated that enclomiphene 12.5 mg and 25 mg daily restored morning testosterone to 300 ng/dL or above in 75% and 84% of subjects, respectively, after 3 months, while topical testosterone gel produced comparable serum levels but significantly suppressed sperm concentration [3].

The drug has not received final FDA approval for a commercially marketed oral tablet for male secondary hypogonadism as of mid-2025. Androxal, the lead branded formulation from Repros Therapeutics, received a Complete Response Letter in 2013. The FDA's current list of approved enclomiphene-containing products does not include a standalone oral male hypogonadism indication [4]. That regulatory gap is precisely why compounding pharmacies carry the market in states like Mississippi.

Enclomiphene Citrate Cash Price in Mississippi 2026

The average cash price for compounded enclomiphene citrate at a licensed Mississippi 503A pharmacy runs approximately $90 per month in 2026 for a once-daily oral capsule or tablet at standard doses (12.5 mg to 25 mg). No major retail chain (CVS, Walgreens, Walmart) stocks enclomiphene on its formulary because no brand-name product has received the required FDA approval for this indication, so GoodRx and similar retail-coupon tools return no usable results for most Mississippi ZIP codes.

Compounding prices can vary by 20% to 35% depending on the pharmacy, excipient choices, and capsule versus tablet preparation. A 30-day supply of 12.5 mg capsules often prices slightly lower, sometimes $75 to $85, than a 25 mg tablet formulation at $90 to $110, because higher-dose raw API use raises costs. Patients who negotiate a 90-day supply frequently save $15 to $25 per month versus paying month-to-month [5].

Testosterone testing, which prescribers require at baseline and typically at 6-week and 12-week follow-ups, adds $40 to $120 per draw at Mississippi Quest or LabCorp patient service centers without insurance. At-home dried blood spot panels from telehealth platforms sometimes bundle testing with the prescription, bringing the total monthly cost to $120 to $160 inclusive [6].

The HealthRX Cost Framework for Mississippi patients breaks cost into three tiers:

Tier 1 (Lowest): Compounded enclomiphene from a Mississippi 503A pharmacy, telehealth consult, self-pay labs. Estimated all-in monthly cost: $120 to $160.

Tier 2 (Moderate): Telehealth platform with bundled medication, shipping, and quarterly lab panel. Estimated all-in monthly cost: $160 to $220.

Tier 3 (Highest): In-person Mississippi urology or endocrinology clinic, retail compounding pharmacy, separate lab order. Estimated all-in monthly cost: $200 to $320 depending on specialist co-pay.

Is Compounded Enclomiphene Citrate Legal in Mississippi?

Compounded enclomiphene citrate is legal in Mississippi when dispensed by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies compound non-commercially-available medications for individual patients based on a valid prescription from a licensed practitioner [7]. Mississippi's State Board of Pharmacy licenses and inspects 503A facilities; the board's regulations align with USP Chapter 795 standards for non-sterile compounding [8].

A 503A pharmacy may not compound a drug that is essentially a copy of a commercially approved product in the same strength and dosage form. Because no branded oral enclomiphene tablet for male hypogonadism currently holds FDA marketing approval, 503A pharmacies can legally prepare it for individual prescriptions. If an FDA-approved branded product were to reach market, that legal window could narrow substantially [4].

503B outsourcing facilities, which compound in large batches without patient-specific prescriptions, face stricter FDA oversight. The FDA's current bulk drug substance list does not include enclomiphene as a permitted 503B substance, which means Mississippi patients should confirm their pharmacy holds a 503A, not 503B, designation before filling [7].

Mississippi law also prohibits pharmacies from compounding purely for office stock or resale purposes without patient-specific prescriptions, consistent with federal 503A requirements [8]. Prescribers writing for enclomiphene should include the specific patient name, dose, and diagnosis code on each order.

Mississippi Medicaid Coverage for Enclomiphene Citrate

Mississippi Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The indication is off-label, and Mississippi's Division of Medicaid formulary does not list the compound under its preferred drug list as of 2025 to 2026 [9]. Prior authorization pathways for off-label SERM use in male hypogonadism are not established within the Mississippi Medicaid fee-for-service program.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that clomiphene and its isomers "may be considered as an alternative to testosterone therapy in selected patients," but stops short of recommending them as first-line treatment [10]. That qualified language gives payers a basis to deny coverage as investigational. Mississippi Medicaid managed care organizations, including Magnolia Health and UnitedHealthcare Community Plan of Mississippi, follow similar formulary restrictions.

Patients enrolled in Medicaid who use enclomiphene must pay out-of-pocket or seek assistance through manufacturer programs. Because compounded drugs lack NDC numbers recognized by pharmacy benefit managers, standard point-of-sale adjudication rarely applies [9].

Commercial Insurance Coverage for Enclomiphene Citrate in Mississippi

Most Mississippi commercial insurance plans, including BlueCross BlueShield of Mississippi, Humana, and Cigna marketplace products, do not cover compounded enclomiphene citrate as a covered pharmacy benefit. Coverage denials typically cite one or more of three reasons: the drug lacks an FDA-approved indication for the submitted diagnosis, it is a compounded preparation without an NDC, or the plan excludes "lifestyle" or fertility-adjacent therapies.

A small number of employer self-insured plans have added enclomiphene to their specialty formularies after negotiations with pharmacy benefit managers. Patients should call the member services number on their insurance card and ask specifically whether CPT procedure code 99070 (supply of drugs) or J-code billing applies, and whether a medical benefit (rather than pharmacy benefit) exception pathway exists [11].

Appeals are possible. The Endocrine Society guideline language supporting SERMs in secondary hypogonadism [10], combined with a physician letter documenting prior testosterone level results and the clinical rationale for fertility preservation, raises the probability of a successful appeal. A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that written clinical appeals accompanied by specialty society guideline citations succeeded roughly 40% to 60% of the time across all specialty drug classes [12].

Telehealth Prescribing of Enclomiphene in Mississippi

Telehealth prescribing is fully available in Mississippi for enclomiphene citrate. Mississippi enacted permanent telehealth parity legislation in 2019 (House Bill 1302), which requires that services covered in-person be covered at parity for synchronous audio-video telehealth visits [13]. The law applies to commercial insurers; Medicaid telehealth parity rules follow CMS guidance separately.

A prescriber must hold an active Mississippi medical license or qualify under the Interstate Medical Licensure Compact, of which Mississippi is a member state. The prescriber must establish a valid patient-provider relationship before writing a Schedule-exempt controlled substance or a non-controlled medication like enclomiphene [13]. Enclomiphene is not a controlled substance, which simplifies the telehealth prescribing pathway compared to, for example, testosterone cypionate (Schedule III).

After an audio-video consultation and review of lab results, the prescriber sends the prescription electronically to the patient's chosen 503A compounding pharmacy. Shipping within Mississippi typically takes 2 to 5 business days. Several national telehealth platforms serving Mississippi bundle the consult fee, compounded enclomiphene, and quarterly labs for $160 to $220 per month inclusive, which undercuts the Tier 3 in-person model by $40 to $100 [14].

How Enclomiphene Works: The Clinical Evidence Base

The pharmacology of enclomiphene differs from its cis-isomer zuclomiphene in one important way. Enclomiphene clears the body within 24 to 48 hours, while zuclomiphene accumulates with long-term dosing [3]. In the Phase III Androxal program, enclomiphene 25 mg daily raised mean morning testosterone from 232 ng/dL to 400 ng/dL at 16 weeks (P<0.001 versus baseline) while sperm concentration fell by only 0.2 million/mL, a non-significant change versus placebo [3].

By contrast, the topical testosterone comparator arm in the same trial showed a mean sperm concentration decline from 38 million/mL to 16 million/mL at 16 weeks (P<0.001) [3]. For Mississippi men who express interest in future fertility or who have already experienced testosterone-suppression-related fertility impairment, that difference is clinically relevant.

The American Urological Association's 2022 guideline on testosterone deficiency notes that clomiphene citrate (and by extension its active isomer enclomiphene) may be used for secondary hypogonadism when fertility preservation is desired [15]. Endocrine Society guidance from 2018 similarly acknowledges SERMs as a management option [10]. Neither guideline specifies a required serum testosterone threshold for initiating treatment, but most clinicians use a morning total testosterone below 300 ng/dL confirmed on two separate draws as the standard trigger, following Endocrine Society thresholds [10].

FSH response to enclomiphene also matters. A 2018 paper in Translational Andrology and Urology (N=93) found that men with secondary hypogonadism who had baseline FSH below 8 IU/L showed the strongest testosterone response to enclomiphene 12.5 mg at 12 weeks, with 82% achieving total testosterone above 300 ng/dL [16]. Baseline FSH testing costs $15 to $40 at Mississippi LabCorp patient service centers.

Side Effects and Monitoring Relevant to Cost Planning

Monitoring requirements directly affect total cost. Enclomiphene raises estradiol in parallel with testosterone, and some patients require adjunctive low-dose anastrozole (0.5 mg to 1 mg twice weekly) to control estrogenic side effects including gynecomastia or mood changes [3]. Anastrozole at compounded doses adds $20 to $50 per month to the total.

Hematocrit elevation is less common with enclomiphene than with injectable testosterone, but clinicians still check a complete blood count at 3 months and annually thereafter [15]. A standard CBC at Mississippi outpatient labs runs $20 to $40 without insurance. Visual disturbances, a known SERM class effect, should prompt an ophthalmology referral; the incidence in enclomiphene trials was below 2% [3].

The full monitoring schedule over 12 months, including baseline testosterone, LH, FSH, estradiol, CBC, and lipid panel, can add $180 to $400 in laboratory costs for uninsured Mississippi patients. Factored into the monthly cost, that is an additional $15 to $33 per month over the first year [6].

Discount Programs and Cost-Reduction Strategies in Mississippi

Several strategies reduce the monthly cost of enclomiphene in Mississippi below the $90 compounded baseline.

Manufacturer assistance: No direct manufacturer coupon exists for compounded enclomiphene because it lacks a proprietary NDC. Branded programs from Repros Therapeutics were discontinued with the Androxal program halt [4].

Compounding pharmacy membership programs: Some Mississippi 503A pharmacies and national compounding networks offer subscription pricing. Patients who commit to a 3-month or 6-month supply often receive a 10% to 15% discount versus monthly billing, bringing a 25 mg daily capsule from $90 to roughly $77 to $81 per month.

Telehealth bundled plans: Platforms like those serving Mississippi men's health often bundle medication, shipping, and lab panels. When the lab costs are included in the bundle, the effective per-unit medication price can fall below $70 in the all-in comparison.

HSA and FSA accounts: Enclomiphene dispensed against a valid prescription qualifies as an eligible medical expense under IRS Publication 502. Mississippi patients with employer-sponsored health savings accounts or flexible spending accounts can pay for enclomiphene, labs, and telehealth visits pre-tax, reducing effective cost by 22% to 32% depending on marginal tax rate [17].

GoodRx and pharmacy discount cards: These tools do not apply to compounded medications without retail NDC numbers. Patients should not expect GoodRx pricing to work at a 503A compounding pharmacy [5].

Finding a Mississippi-Licensed 503A Compounding Pharmacy

The Mississippi State Board of Pharmacy maintains a public license lookup at its official portal, where patients can verify that a pharmacy holds an active 503A compounding designation before submitting a prescription. Patients should ask each pharmacy two direct questions: whether they compound enclomiphene citrate using pharmaceutical-grade API from an FDA-registered supplier, and whether their USP 795 compliance has been independently verified within the past 12 months [8].

Quality matters beyond price. A 2022 FDA inspection report summary found that 36% of 503A pharmacies surveyed nationwide had at least one significant deviation from USP standards, the most common being inadequate potency verification of the finished compound [18]. A pharmacy that charges $85 per month with verified potency testing offers better clinical value than one charging $70 with no third-party certificate of analysis.

Patients can request a certificate of analysis from the compounding pharmacy before filling their first prescription. A legitimate 503A pharmacy will provide this document, confirming API identity, potency (typically 95% to 105% of labeled strength), and absence of microbial contamination [18].